FCMI
DMTX

Foresite Capital Management III’s Dimension Therapeutics, Inc DMTX Stock Holding History

Foresite Capital Management III’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-98,297
Closed -$770K – 26
2016
Q1 		$770K Hold
98,297
– – 0.6% 20
2015
Q4 		$1.11M Buy
+98,297
New +$1.24M 0.98% 18

Other funds holding DMTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Foresite Capital Management III's DMTX Position: Q2 2016 in Review

Foresite Capital Management III sold out of Dimension Therapeutics, Inc (DMTX) in Q2 2016, closing a stake of 98,297 shares — an estimated $770K sold.

Foresite Capital Management III first reported a position in DMTX in Q4 2015 and held it in 2 quarters. The position peaked at $1.11M in Q4 2015. 52 funds tracked by Wall St. Rank hold DMTX as of Q2 2016.

  • Foresite Capital Management III reported no remaining Dimension Therapeutics, Inc position as of Q2 2016 after selling out during the quarter.
  • Foresite Capital Management III sold 98,297 Dimension Therapeutics, Inc shares in Q2 2016, an estimated $770K.
  • Foresite Capital Management III first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 2 quarters.
  • Foresite Capital Management III's Dimension Therapeutics, Inc position peaked at $1.11M in Q4 2015.
  • 52 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q2 2016.

Based on Foresite Capital Management III's 13F filing for Q2 2016, filed 12 Aug 2016.